 | In Vitro Phenotypic Assays as Predictive Tools to Drive Parkinson’s Disease Drug DiscoveryThe discovery and validation of novel targets are essential to fuel a healthy drug pipeline, and in vitro phenotypic assays are instrumental for delivering valid targets and promising lead molecules. View this webinar to learn more about our in vitro assay capabilities performed in clinically relevant cell models, where we’ll highlight key endpoints for neurodegenerative diseases such as a-synuclein aggregation, Ab toxicity and autophagy/mitophagy readouts.
|
 | A Comprehensive Review of Biomarker Endpoints In In Vivo Models of Parkinson’s DiseaseTherapeutic approaches for Parkinson’s disease are either focused on disease modification (a-synuclein or MPTP models) or symptom management (haloperidol or 6-OHDA models). Our scientists have validated available PD models for changes in fine motor skills, L-dopa-induced dyskinesias, drug-induced jaw movements, and non-motor endpoints such as cognition, constipation, and EDS. Additionally, we have also tested dopamine and other neurotransmitter levels in brain compartments of rodent and large animal models via microdialysis sampling. View this webinar for a comprehensive review of the validation data from established and novel animal models of Parkinson’s disease.
|